How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Has all of the relevant evidence been taken into account?

  • Question on Document

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Document

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Document

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Guidance assessment consultation document for GID-HTE10020 Digital health technologies to help manage symptoms of psychosis and prevent relapse: early value assessment

Closed for comments This consultation ended on at   Request commenting lead permission

2 The technologies

2.1

NICE has assessed 3 digital health technologies for managing symptoms of psychosis or preventing relapse. All technologies are delivered or supported by a mental health professional trained in the technology. The criteria for including technologies in this assessment are in the final scope for this guidance on the NICE website. The technologies are:

  • AVATAR Therapy for managing distressing auditory verbal hallucinations (hearing voices). It allows people to create a digital representation (an avatar) of their distressing voice. Over 6 to 12 sessions, the person is encouraged to engage in dialogue with this avatar to take power and control within the conversation. The avatar is voiced by a mental health professional, trained in this technology. This allows a 3-way conversation between the person hearing voices, the avatar and the mental health professional. AVATAR Therapy can be delivered as a standalone intervention by a trained mental health professional. It can also be used as a component of standard care psychological interventions such as cognitive behavioural therapy for psychosis (CBTp).

  • SlowMo for managing distressing thoughts and paranoia in people with psychosis. It is a blended digital therapy that helps people to be aware of a symptom of psychosis, fast thinking and reasoning, and helps slow down thoughts. It is delivered in 8 sessions by a mental health professional, trained in use of this technology, who can access modules and interactive features using the SlowMo web app. Content is also synchronised to a mobile app on the patient's smartphone for use outside of sessions. SlowMo can be delivered as a standalone intervention by a trained mental health professional. It can also be used as a component of standard care psychological interventions such as CBTp.

  • CareLoop for remote monitoring of symptoms of psychosis. It aims to prevent relapse by identifying worsening of symptoms. People regularly record symptoms, thoughts and feelings in an app using questionnaires and journal entries. CareLoop includes an algorithm that aims to recognise worsening mental health and potential relapse. This information is shared with mental health professionals who can then provide early interventions to prevent relapse.

Care pathway

2.2

The scope for this early value assessment included a target population of people aged 14 years and over with primary psychosis. Treatment and care for psychosis in people aged 18 years and over is usually managed in community mental health services including early intervention in psychosis services and community mental health teams. NICE's guideline on psychosis and schizophrenia in adults recommends that adults with a first episode or first presentation of psychosis should have an assessment and treatment in early intervention in psychosis services. Longer-term treatment and care are usually then provided by community mental health teams. NICE's guideline on psychosis and schizophrenia in children and young people recommends that children and young people who present for the first time with sustained psychosis symptoms should be urgently referred to child and adolescent mental health services or an early intervention in psychosis service. Longer-term treatment and care may then be provided in primary care or secondary care, including early intervention in psychosis services. For adults, children and young people, inpatient hospital care may be considered by care providers for subsequent acute episodes of psychosis.

2.3

People with psychosis should be offered antipsychotic medicine and psychological interventions including CBTp and family intervention. If a person's symptoms respond well to treatment and remain stable, they should be offered the option to return to primary care for further management. Monitoring for relapse prevention varies across NHS services. It usually involves regular follow-ups with a care coordinator and reviews with a psychiatrist. The clinical experts advised that there is no formal relapse prevention process. People may be at high risk of relapse if there are changes to their medicine or other parts of their treatment or support. If relapse is suspected, treatment should be provided in line with a person's crisis plan, and referral to secondary care may be considered.

2.4

Clinical and patient experts advised that access to CBTp varies and is limited for some people. Most adults with psychosis who are having treatment outside of early intervention in psychosis services do not have the psychological interventions recommended by NICE's guideline on psychosis and schizophrenia. Digital health technologies may increase access to care by offering another option for managing symptoms of psychosis. Some technologies are designed to monitor symptoms and to help detect relapses earlier, so people could be treated sooner. Digital health technologies would be used as an alternative or addition to standard care.

The comparator

2.5

The comparator for digital health technologies for managing symptoms of psychosis (AVATAR Therapy and SlowMo) is CBTp. Other psychological interventions such as group therapy or supportive counselling may be offered instead for some people on waiting lists to have CBTp. In some areas, people on waiting lists may not be offered any psychological support. Clinical experts advised that digital health technologies would not be offered instead of antipsychotic medicine. So, this was not a comparator in this assessment.

2.6

The comparator for digital health technologies for preventing relapse (CareLoop) is healthcare professional follow ups and reviews.